COLUMBIA, MD and TORONTO--(Marketwired - Aug 12, 2013) - Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that an audio interview with John Mon, COO of Medifocus, Inc. (TSX VENTURE: MFS) (OTCQX: MDFZF), with Charles Moskowitz of the "Money Info Show hosted by Bill Chippas" is now available and can be heard at http://www.princetonresearch.com/medical-stock-news-medifocus-money-info/
The Money Info Show airs at 10:00AM to 11:00AM EDT every Tuesday and can be heard at www.princetonresearch.com/money-info-live.htm
Last week, John was the featured speaker on Small Cap Voice.com which can be heard at
http://smallcapvoice.com/blog/7-29-13-smallcapvoice-interview-with-medifocus-inc-mdfzf
John discussed the recent news for the Company, the business models and markets for their technologies, in addition to the goals of Medifocus in 2013, and beyond.
"We are excited about our current position in the BPH market and are extremely optimistic about moving forward in Phase III with our breast cancer treatment technology," explained John Mon. "We are working to sustain and increase shareholder value through executing on our accelerated growth model in 2013 and beyond."
Mr. Mon was previously V.P. of business and product development, General Manager, and Director of Celsion. He achieved FDA approvals for IDE/PMA/510K submissions, and has worked with clinicians, engineers, and patent attorneys on thermotherapy and breast-cancer-related devices. Mr. Mon has co-authored several scholarly articles and holds many granted and pending patents in the area of thermotherapy for the treatment of cancer and other diseases.
Get More Corporate and Stock Quote information at: http://medifocusinc.com/index.php/stock-information/
See Medifocus Corporate Fact Sheet March 2013: http://www.princetonresearch.com/Medifocus-Factsheet-March-2013-Final.pdf
Visit the corporate web site: www.medifocusinc.com
About Medifocus, Inc.
Medifocus, Inc. owns two fully developed technology platforms with comprehensive US and international patent protection: (1) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The U.S. FDA approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia ("BPH") was developed based on the Endo-thermotherapy and is currently generating revenue, and (2) The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System, developed from the APA technology platform has received approval from the U.S. FDA and Health Canada to conduct the pivotal Phase III clinical trials. The Company believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers. Please visit www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.